Standard chemoradiation outperforms de-intensified treatments in HPV-associated oropharyngeal cancer

Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized phase II/III trial after patients in the control arm reached a record high, two-year progression-free survival rate of 98%.

Year in Review: Atopic Dermatitis

New therapies, expanding uses for existing therapies, and links between atopic dermatitis (AD) and multiple inflammatory conditions have made headlines so far this year. IL-13

November 2, 2023

Pharmaceutical Technology | Drug Development News & Views Updated DailyHome – Pharmaceutical Technology

Latest Issue Pharma Technology Focus Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read

September 27, 2024

Year in Review: Age-Related Macular Degeneration

First approvals for geographic atrophy (GA), puzzling side effects of the new GA drugs, and hits and misses with artificial intelligence (AI) applied to retinal

November 2, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.